In a remarkable response to the escalating Ebola outbreak in the Democratic Republic of the Congo (DRC), researchers have initiated a groundbreaking treatment trial just six weeks after the World Health Organization (WHO) declared the situation a public health emergency. This swift action aims to evaluate the effectiveness of two drugs, with the potential to significantly reduce mortality rates associated with the Bundibugyo strain of the virus.
Record-Setting Trial Commences
As of 9 July, the DRC has reported 1,792 confirmed Ebola cases, resulting in 625 fatalities. The Bundibugyo strain, while generally less lethal than the more notorious Zaire strain, still claims the lives of approximately one in three infected individuals. The trial, which is unprecedented in its rapid setup, is taking place in the Ituri region, where local healthcare systems are under immense pressure to manage the outbreak.
Neema Haba, a local resident and mother of three, expressed the community’s urgent need for progress. “I hope these drug trials proceed quickly,” she stated. “Financially, we are being driven to the brink by this outbreak and nothing is going right.”
Community Challenges and Healthcare Strains
The healthcare response to this outbreak relies heavily on traditional methods: identifying and isolating cases, and tracing their contacts. Despite efforts, only about 75% of known contacts are being monitored, largely due to a pervasive mistrust of health authorities and a highly mobile population. This situation has been exacerbated by recent protests from frontline workers over unpaid wages, further complicating the response.
The dangers of handling Ebola victims are significant. Ovide Maliabo, a driver for a safe burial team, described the perilous nature of their work. “At one point, we narrowly escaped being lynched,” he recounted, highlighting the community’s fear and suspicion towards health workers. Bahati John, leader of the burial team, echoed these sentiments, stating, “We haven’t seen a single penny since we started working.”
Innovative Drug Trials Underway
The Partners treatment trial involves the investigation of two drugs: remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. The trial will randomly assign patients to receive either drug, a combination of both, or standard supportive care. Both medications have shown promise in animal studies against the Bundibugyo strain, and researchers are keen to assess their efficacy in human subjects.
Professor Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp explained, “These two drugs actually have been proven to work against the Bundibugyo virus in animal models. Now we need to test it in humans. Basically, what we want to see is if they indeed can lower mortality.”
Notably, the trial is inclusive, allowing patients of all ages, including pregnant and breastfeeding women, to participate. Liesenborghs emphasised the potential life-saving benefits of these treatments, stating, “Here the benefit is potentially very high because you offer a potentially life-saving treatment to someone who has a very high chance of dying.”
A Collaborative Effort with Global Support
The WHO has facilitated the provision of sufficient drug supplies for 1,200 patients, with discussions ongoing to ensure access to treatments post-trial. Prof Amanda Rojek from the University of Oxford praised the rapid mobilization of resources in DRC, contrasting it with the lengthy delays seen during previous outbreaks. “We’re very proud of the team led by INRB that we’ve managed to achieve this in just six weeks,” she noted.
As part of ongoing efforts, a second trial is set to commence, which will examine the efficacy of a drug called obeldesivir in preventing disease development among individuals who have been in contact with confirmed cases. The Africa CDC has indicated that this trial requires approximately $18 million to proceed, with $6 million currently committed.
Why it Matters
The establishment of these trials in the DRC amidst a severe Ebola outbreak exemplifies the urgent need for innovative medical responses in crisis situations. As healthcare professionals work tirelessly to combat the virus, successful outcomes from these trials could pave the way for effective treatments, ultimately saving countless lives and restoring trust in public health interventions. Such advancements are not only critical for the DRC but also set a precedent for future responses to global health emergencies.